Los Angeles, CA, United States of America

John Nicoll

This inventor holds 6 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignee: University of California. Active years: 2009-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Nicoll. Retrieved from https://idiyas.com/inventor/john-nicoll

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 3)

% Patents Active = 16.7

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 8(Granted Patents)

Location History:

Los Angeles, CA (US) (2009 - 2015)
Sylmar, CA (US) (2018)

Company Filing History:

6 out of 16,025

University of California

patents

Years Active: 2009-2018

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9994910 - Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571 (2018-06-12),

2. 9085644 - Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571 (2015-07-21),

3. 9056924 - Mutations in the BCR-ABL tyrosine kinase associated with resistance to STI-571 (2015-06-16),

4. 8697348 - Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571 (2014-04-15),

5. 8586291 - Mutations in the Bcr-Abl tyrosine kinase associated with resistance to ST1-571 (2013-11-19),

6. 7521175 - Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571 (2009-04-21),

Title: The Innovative Mind of John Nicoll: Pioneering Cancer Therapies

Introduction: John Nicoll, a prolific inventor based in Los Angeles, CA, has made significant contributions to the field of medical research and cancer therapies. With a total of 6 patents to his name, Nicoll's groundbreaking work continues to shape the landscape of modern medicine.

Latest Patents: Among Nicoll's latest patents is the discovery of Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571. This invention unveils novel genes and their encoded proteins, such as T315I Bcr-Abl, offering diagnostic and therapeutic methods for managing various cancers expressing MARS. Additionally, the patent outlines innovative approaches for identifying molecules that interact with and modulate the functional activity of MARS.

Career Highlights: Nicoll's impressive career includes impactful tenures at esteemed institutions like the University of California and The Regents of the University of California. Through his relentless pursuit of scientific advancement, Nicoll has revolutionized the understanding and treatment of cancer, leaving an indelible mark on the medical community.

Collaborations: Throughout his career, Nicoll has collaborated with esteemed professionals in the field, including Charles L Sawyers and Mercedes E Gorre. These partnerships have fostered a culture of innovation and shared knowledge, leading to groundbreaking research and advancements in cancer therapeutics.

Conclusion: John Nicoll's pioneering spirit and unwavering dedication to scientific discovery have solidified his legacy as a trailblazer in the realm of medical research. His innovative patent portfolio and collaborative efforts stand as a testament to his profound impact on the field of oncology, offering hope and healing to countless individuals affected by cancer.

Profile summary based on public USPTO records.